<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03616015</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A00676-49</org_study_id>
    <nct_id>NCT03616015</nct_id>
  </id_info>
  <brief_title>Dysbiosis and Immune Reconstitution After Allo-HSCT</brief_title>
  <acronym>PARI-DYS</acronym>
  <official_title>Intestinal Dysbiosis and Immune Reconstitution After Allogeneic Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preliminary (proof of concept), monocentric, interventional, prospective, non-randomized and&#xD;
      analytic trial designed to simultaneously explore intestinal microbiota changes and early&#xD;
      post-transplant immune reconstitution, and to correlate biological data with clinical data&#xD;
      (antibiotics use, stress level, GVHD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the major curative&#xD;
      therapeutic approach for hematologic neoplasms. After HSCT, patients have a compromised GI&#xD;
      mucosal barrier and an altered microbiota, also called dysbiosis. The later could be due to&#xD;
      conditioning or use of broad-spectrum antibiotics, and could be accentuate by stress&#xD;
      encountered by patients during their therapy management. Recent data have shown that&#xD;
      alterations in the intestinal flora are associated with bad outcome, particularly with&#xD;
      graft-versus-host disease (GVHD), bacteremia, and reduced overall survival&#xD;
      post-transplantation. How intestinal bacteria can modulate the risk of relapse after HSCT is&#xD;
      yet unknown. The scientists hypothesize that the variation of some bacterial taxa may&#xD;
      influence post-transplant immune reconstitution, particularly invariant Natural Killer T&#xD;
      cells.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>quality of iNKT reconstitution after HSCT (good/poor)</measure>
    <time_frame>Day 90,</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>gut microbiota composition</measure>
    <time_frame>Day 0, Day 15, Day 30, Day 90</time_frame>
    <description>relative abundance of intestinal bacterial taxa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immune reconstitution after HSCT (other immune cells)</measure>
    <time_frame>Day 15, Day 30, Day 60, Day 90, Day 180, Year 1, Year 2</time_frame>
    <description>quantification of Tregs, MDSC, MAIT, T lymphocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GVH disease</measure>
    <time_frame>Day 30, Day 60, Day 90</time_frame>
    <description>yes/not</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>use of antibiotics</measure>
    <time_frame>Day 0, Day 15, Day 30, Day 60, Day 90</time_frame>
    <description>yes/not (molecules, delay, posology)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of stress</measure>
    <time_frame>Day -8, Day 15, Day 30, Day 90</time_frame>
    <description>test of Cohen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of anxiety</measure>
    <time_frame>Day -8, Day 15, Day 30, Day 90</time_frame>
    <description>test of Spielberger</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of iNKT reconstitution after HSCT (good/poor)</measure>
    <time_frame>Day 15, Day 30, Day 60, Day 180, Year 1, Year2</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Patient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For all patients included in the study, the following interventions will be performed :&#xD;
several blood samples (quantity collected requiring classification of this study as interventional according to French law)&#xD;
several fecal samples&#xD;
anxiety tests&#xD;
stress tests</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood samples</intervention_name>
    <description>20 to 30 ml of blood sample (D0, D15, D30, D60, D90, D180, Y1, Y2)</description>
    <arm_group_label>Patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>fecal samples</intervention_name>
    <description>1 g of feces (D-8, D0, D15, D30, D90)</description>
    <arm_group_label>Patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Anxiety test</intervention_name>
    <description>Test of Spielberger</description>
    <arm_group_label>Patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Stress test</intervention_name>
    <description>Test of Cohen</description>
    <arm_group_label>Patient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients &gt; 18 years affiliated to a social security system&#xD;
&#xD;
          -  Patients followed at the hospital of Nancy for a allogeneic hematopoietic cell&#xD;
             transplantation (HLA matched donor)&#xD;
&#xD;
          -  Graft of peripheral blood stem cell&#xD;
&#xD;
          -  GVHD prophylaxis by ciclosporin and antilymphocyte serum +/- mycophenolate mofetil or&#xD;
             methotrexate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV+ patients&#xD;
&#xD;
          -  Patients with active HBV or HCV&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Corentine ALAUZET, Dr</last_name>
    <phone>0383153938</phone>
    <phone_ext>+33</phone_ext>
    <email>c.alauzet@chru-nancy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Thérèse RUBIO, Pr</last_name>
    <phone>0383153257</phone>
    <phone_ext>+33</phone_ext>
    <email>m.rubio@chru-nancy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>RUBIO Marie-Thérèse</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Thérèse RUBIO, PU-PH</last_name>
      <phone>383153282</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>July 19, 2018</study_first_submitted>
  <study_first_submitted_qc>August 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2018</study_first_posted>
  <last_update_submitted>January 30, 2019</last_update_submitted>
  <last_update_submitted_qc>January 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HSCT</keyword>
  <keyword>intestinal dysbiosis</keyword>
  <keyword>immune reconstitution</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysbiosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

